Repligen Corp. Beats Estimates Despite Third Quarter Loss

Bioprocessing firm Repligen Corp. outperformed revenue expectations this quarter despite reporting a $38.4 million net loss.

Updated on Oct. 27, 2026 in Corporate Finance

Repligen Corp. Beats Estimates Despite Third Quarter Loss

Live Poll

Does meeting earnings expectations make you more confident in your personal investment plans?

Waltham-based Repligen Corp. reported a $38.4 million net loss for the third quarter of 2026, even as it outperformed analyst expectations on revenue. The bioprocessing firm cited asset impairment and amortization costs as key factors influencing the bottom-line result.

Why it matters

Understanding how a company navigates high one-time costs like asset impairments against its operational revenue is crucial for operators assessing sector health. Repligen's ability to exceed analyst forecasts despite a net loss signals relative stability in its underlying business model.

Repligen posted a $38.4 million net loss for the third quarter, equal to 68 cents per share. This result is balanced against adjusted earnings of 53 cents per share, which surpassed the 46-cent estimate from analysts at Zacks Investment Research.

The players

Repligen Corp.

A Waltham-based life sciences company that manufactures bioprocessing technologies for the biopharmaceutical industry.

The details

The divergence between the net loss and adjusted earnings stems from the company's treatment of specific accounting factors. Repligen adjusted its results to remove the impact of asset impairment and amortization costs, allowing for a clearer view of core operational performance. This approach provides a clearer picture of profitability for stakeholders while acknowledging the immediate drag of these non-cash charges on the balance sheet.

Q3 2026
Tuesday, October 27, 2026

Market Landscape

Repligen's performance follows the pattern of bioprocessing sector asset impairment write-downs often seen during fiscal recalibrations. It demonstrates how mid-market firms maintain investor confidence by isolating core operational metrics from non-recurring accounting charges.

Operators should monitor whether these asset impairment costs lead to broader structural changes or are isolated to the third quarter. The company's full-year outlook of $2.05 to $2.09 per share serves as a key benchmark for internal planning and sector demand forecasting.

The takeaway

Repligen demonstrates that hitting revenue targets often hinges on how transparently a company separates core performance from accounting adjustments. Operators should track the company's full-year guidance range of $2.05 to $2.09 per share as a signal for the broader bioprocessing market demand.